Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America

AIDS

Volumn 26, Issue 11, 2012, Pages 1415-1423

  Genberg, Becky L ^a   Wilson, Ira B ^a   Bangsberg, David R ^b   Arnsten, Julia ^c   Goggin, Kathy ^d   Remien, Robert H ^e   Simoni, Jane ^f   Gross, Robert ^g   Reynolds, Nancy ^h   Rosen, Marc ^h   Liu, Honghu ⁱ  

^a BROWN UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral therapy; medication adherence; protease inhibitors; reverse transcriptase inhibitors; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; DOSE RESPONSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NORTH AMERICA; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84863698764     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328354bed6     Document Type: Article

References (22)

1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183. (Pubitemid 32549871)
2. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of selfreport and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423. (Pubitemid 32955198)
3. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30. (Pubitemid 30432540)
4. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109-2117. (Pubitemid 33101818)
5. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977. (Pubitemid 32466236)
6. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3):S103-S106. (Pubitemid 35453567)
7. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971. (Pubitemid 46684328)
8. Parienti JJ, Ragland K, Lucht F, de la Blanchardiere A, Dargere S, Yazdanpanah Y, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis 2010; 50:1192-1197.
9. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al. Predictors of virologic failure and resistance in HIVinfected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316. (Pubitemid 38608576)
10. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-tomoderate adherence levels. PLoS One 2008; 3:e2783.
11. Wagner GJ, Goggin K, Remien RH, Rosen MI, Simoni J, Bangsberg DR, et al. A Closer Look at Depression and Its Relationship to HIV Antiretroviral Adherence. Ann Behav Med 2011; 42:352-360.
12. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941. (Pubitemid 44435526)
13. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-396. (Pubitemid 36960649)
14. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37. (Pubitemid 37338886)
15. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
16. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 2010; 5:e10307.
17. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the fivedays-on, two-days-off (FOTO) study. HIV Clinical Trials 2007; 8:19-23. (Pubitemid 46542906)
18. Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 2010; 14:1340-1346.
19. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health 2011; 16:1297-1313.
20. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3):S123-S127. (Pubitemid 35453571)
21. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.
22. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60:578-586. (Pubitemid 44032819)